Table 1.
Baseline characteristics in all patients with COVID-19/HIV- coinfection
| Variables | Total (n = 12) |
|---|---|
| Gender (n, %) | |
| Male | 8 (67%) |
| Female | 4 (33%) |
| Age (y), median (Q1, Q3) | 48 (33·5, 51) |
| Complete Blood Count, median (Q1, Q3) | |
| WBC (× 109/L) | 3·56 (2·96, 5·26) |
| Neutrophils (× 109/L) | 2·48 (1·73, 2·81) |
| Lymphocytes (× 109/L) | 1·19 (0·76, 1·65) |
| Monocytes (× 109/L) | 0·31 (0·21, 0·40) |
| Eosinophils (× 109/L) | 0·09 (0·02, 0·17) |
| Basophils (× 109/L) | 0·02 (0·01, 0·03) |
| Hemoglobin (g/L) | 121·5 (94·75, 128·75) |
| Platelet (× 109/L) | 157 (134, 207) |
| d-Dimmer | 1·075 (0·4075, 1·590) |
| Coexisting disorders (n, %) | |
| AIDS | 12 (100%) |
| Hepatitis B | 1 (8%) |
| Hepatitis C | 2 (17%) |
| Syphilis | 1 (8%) |
| Hypertension | 1 (8%) |
| Diabetes | 2 (17%) |
| Renal insufficiency | 2 (17%) |
| NTM | 1 (8%) |
| Vaccination (n, %) | |
| Yes | 0 (0%) |
| No | 12 (100%) |
| Admission clinical classification (n, %) | |
| Mild | 7 (58%) |
| Moderate | 5 (42%) |
| Severe | 0 (0%) |
| Critical | 0 (0%) |
| Treatment—no, % | |
| Oxygen inhalation | 2 (17%) |
| Chinese medicine | 12 (100%) |
| Antiretroviral treatment (ART) | 12 (100%) |
| Low molecular weight heparins calcium | 10 (83%) |
| Intravenous immunoglobulin | 7 (58%) |
| Azvudine | 6 (50%) |
| Thymalfasin | 11 (92%) |
| Convalescent plasma | 6 (50%) |
| Combined medication of BRII/196 and BRII/198 | 8 (67%) |
| IFN-α | 1 (8%) |
| IL-2 | 6 (50%) |
| Clinical outcome | |
| Hospital discharge | 11 (92%) |
| Death | 0 (0%) |
AIDS Acquired Immune Deficiency Syndrome, NTM nontuberculous mycobacteria; IFN interferon, IL interleukin